Company Overview

Isodiol International Inc. (OTC: ISOLF) is a Canadian cannabis and hemp-derived wellness company that historically focused on the development, marketing, and distribution of cannabidiol (CBD) consumer products and related pharmaceutical-grade ingredients. The company operated within the broader cannabis, nutraceutical, and health and wellness industries, with product categories that included CBD tinctures, topicals, isolates, and hemp-derived consumer formulations. Public disclosures and historical investor materials indicate that the company positioned itself around vertically integrated cannabinoid sourcing and international distribution capabilities.

The company’s business model was primarily driven by sales of hemp-derived CBD products and intellectual property related to cannabinoid formulations and processing technologies. Isodiol pursued growth through acquisitions, licensing arrangements, and international expansion initiatives during the peak growth period of the global cannabis sector between 2017 and 2019. The company evolved from an early-stage cannabis wellness platform into a multi-brand operator with interests spanning consumer wellness, pharmaceutical applications, and industrial hemp derivatives. However, publicly available information regarding current operating scale and active commercial operations has been limited in recent years, and some operational data is inconclusive based on available public sources.

Business Operations

Historically, Isodiol organized operations around cannabinoid-based product development, manufacturing relationships, and global distribution partnerships. The company’s reported business activities included sales of CBD consumer products, bulk hemp-derived ingredients, and proprietary cannabinoid formulations. Through subsidiaries and affiliated entities, Isodiol pursued opportunities in white-label manufacturing, pharmaceutical research applications, and international hemp sourcing. Revenue generation was tied primarily to wellness-product sales and distribution agreements across North America and selected international markets.

The company previously disclosed operations and partnerships spanning the United States, Canada, Europe, Asia, and Latin America. Isodiol also announced relationships involving cannabinoid extraction technologies and pharmaceutical development initiatives through various subsidiaries and acquisition targets. Historically referenced subsidiaries and business units included Iso-Sport, BSPG Laboratories, and other cannabinoid-focused operating entities. Some previously announced acquisitions and joint ventures appear to have undergone restructuring or produced limited subsequent disclosure, and certain operational details remain inconclusive based on available public sources and filings.

Strategic Position & Investments

Isodiol’s strategic direction centered on establishing a global footprint in hemp-derived cannabinoids and positioning itself as a supplier of pharmaceutical-grade CBD ingredients and consumer wellness products. The company pursued aggressive expansion through acquisitions, licensing agreements, and cross-border distribution arrangements during the rapid growth phase of the cannabis industry. Publicly disclosed transactions historically included investments in formulation technologies, sports nutrition products, and cannabinoid research initiatives.

The company also sought exposure to emerging sectors tied to cannabis therapeutics, biosciences, and international hemp commercialization. Historically announced investments and acquisitions included interests in BSPG Laboratories, Iso-Sport, and other cannabinoid-related entities. Public disclosures suggested an emphasis on intellectual property, global supply-chain access, and regulatory positioning in emerging CBD markets. However, the long-term status and financial impact of several announced investments are difficult to verify from recent public disclosures, and certain information is inconclusive based on available public sources.

Geographic Footprint

Isodiol International Inc. was headquartered in Canada and historically maintained operations or commercial relationships across multiple international regions. The company promoted a global expansion strategy with reported activity in North America, Europe, Asia-Pacific, and parts of Latin America. The company’s international positioning was tied to hemp sourcing, cannabinoid distribution, and efforts to enter regulated wellness and pharmaceutical markets.

The company emphasized cross-border partnerships and international distribution during its expansion phase, particularly in the United States and selected European and Asian markets. Historical corporate materials referenced operational and investment exposure in countries with evolving cannabis and hemp regulations. While Isodiol previously presented itself as an internationally diversified cannabinoid company, the current scale of its active global operations is difficult to independently confirm from more recent public reporting.

Leadership & Governance

Isodiol International Inc. underwent multiple leadership and governance changes during its development as a public cannabis company. Earlier public filings and corporate disclosures identified several executives and directors associated with expansion, acquisitions, and international operations. Available public information regarding the company’s most current executive leadership structure is limited, and some governance data is inconclusive based on available public sources.

Key executives and leadership figures historically associated with the company include:

• Marvin Washington – Former Chief Executive Officer
• Dieter MacPherson – Former Chief Executive Officer
• Paul Pendry – Former Chief Executive Officer and Director
• Anton Kovalchuk – Former Chief Financial Officer

The company’s historical leadership strategy emphasized rapid international growth, acquisition-led expansion, and development of cannabinoid-based wellness and pharmaceutical opportunities. Governance and operational transparency became a focus area following regulatory scrutiny and evolving disclosure expectations within the cannabis sector.